Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 49 publications
Reasons for acceptance or nonparticipation in iAdhere: a trial of latent TB infection treatment.
Journal: The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease
Published: October 29, 2024
Evaluating the implementation of weekly rifapentine-isoniazid (3HP) for tuberculosis prevention among people living with HIV in Uganda: A qualitative evaluation of the 3HP Options Trial.
Journal: medRxiv : the preprint server for health sciences
Published: September 24, 2024
Expanding evidence for shortened treatment of latent tuberculosis infection: progress, not perfection.
Journal: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
Published: July 16, 2024
Evaluating the implementation of weekly rifapentine-isoniazid (3HP) for tuberculosis prevention among people living with HIV in Uganda: A qualitative evaluation of the 3HP Options Trial.
Journal: PLOS global public health
Published: May 29, 2024
Using Electronic Health Record Data to Measure the Latent Tuberculosis Infection Care Cascade in Safety-Net Primary Care Clinics.
Journal: AJPM focus
Published: November 09, 2023
Examining Test Cutoffs to Optimize Diagnosis of Latent Tuberculosis Infection in People Born Outside the United States.
Journal: Annals of the American Thoracic Society
Published: May 09, 2023
Using a medication event monitoring system to evaluate self-report and pill count for determining treatment completion with self-administered, once-weekly isoniazid and rifapentine.
Journal: Contemporary clinical trials
Published: December 28, 2022
Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysis.
Journal: The Lancet. Respiratory medicine
Published: December 21, 2022
Symptoms and Systemic Drug Reactions in Persons Receiving Weekly Rifapentine Plus Isoniazid (3HP) Treatment for Latent Tuberculosis Infection.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: November 04, 2022
Variability of interferon-γ release assays in people at high risk of tuberculosis infection or progression to tuberculosis disease living in the United States.
Journal: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
Published: November 19, 2021
Last Updated: 09/26/2026